Biosimilar Landscape in 2024

Navigating the Biosimilar Landscape: What to watch out in 2024 and Beyond

The anticipated expiration of exclusivity rights for major biologics in 2022…


biosimilar

Biosimilars: Enhancing physician uptake in the EU

At the moment, EU physicians seem much more comfortable than their US…


The curious case of biosimilar launches in the US

The Biologics Price Competition and Innovation Act (BPCI Act) of 2009 provided…